A long-standing belief about HIV has quietly shaped how scientists think about the virus. For decades, researchers described ...
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results